(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 14.49% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.43%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Dynavax Technologies's revenue in 2024 is $249,695,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2024 to be $36,358,264,063, with the lowest DVAX revenue forecast at $36,194,458,585, and the highest DVAX revenue forecast at $36,522,069,542. On average, 2 Wall Street analysts forecast DVAX's revenue for 2025 to be $42,151,736,236, with the lowest DVAX revenue forecast at $41,150,557,150, and the highest DVAX revenue forecast at $43,152,915,322.
In 2026, DVAX is forecast to generate $49,342,141,531 in revenue, with the lowest revenue forecast at $46,909,957,783 and the highest revenue forecast at $51,774,325,279.